BioAge Labs Statistics
Total Valuation
BioAge Labs has a market cap or net worth of $716.73 million. The enterprise value is $437.16 million.
Important Dates
The last earnings date was Tuesday, March 24, 2026, before market open.
| Earnings Date | Mar 24, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
BioAge Labs has 44.38 million shares outstanding. The number of shares has increased by 234.99% in one year.
| Current Share Class | 44.38M |
| Shares Outstanding | 44.38M |
| Shares Change (YoY) | +234.99% |
| Shares Change (QoQ) | +0.92% |
| Owned by Insiders (%) | 2.44% |
| Owned by Institutions (%) | 53.93% |
| Float | 37.01M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 79.68 |
| Forward PS | 2.93 |
| PB Ratio | 2.22 |
| P/TBV Ratio | 2.63 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 48.60 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 14.24, with a Debt / Equity ratio of 0.02.
| Current Ratio | 14.24 |
| Quick Ratio | 14.06 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -133.11 |
Financial Efficiency
Return on equity (ROE) is -27.09% and return on invested capital (ROIC) is -19.03%.
| Return on Equity (ROE) | -27.09% |
| Return on Assets (ROA) | -17.76% |
| Return on Invested Capital (ROIC) | -19.03% |
| Return on Capital Employed (ROCE) | -33.77% |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | $145,081 |
| Profits Per Employee | -$1.30M |
| Employee Count | 62 |
| Asset Turnover | 0.03 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +304.76% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | +304.76% |
| 50-Day Moving Average | 19.92 |
| 200-Day Moving Average | 10.33 |
| Relative Strength Index (RSI) | 36.86 |
| Average Volume (20 Days) | 595,564 |
Short Selling Information
The latest short interest is 1.35 million, so 3.04% of the outstanding shares have been sold short.
| Short Interest | 1.35M |
| Short Previous Month | 1.28M |
| Short % of Shares Out | 3.04% |
| Short % of Float | 3.65% |
| Short Ratio (days to cover) | 2.38 |
Income Statement
In the last 12 months, BioAge Labs had revenue of $9.00 million and -$80.61 million in losses. Loss per share was -$2.24.
| Revenue | 9.00M |
| Gross Profit | -64.97M |
| Operating Income | -92.78M |
| Pretax Income | -80.61M |
| Net Income | -80.61M |
| EBITDA | -92.57M |
| EBIT | -92.78M |
| Loss Per Share | -$2.24 |
Full Income StatementBalance Sheet
The company has $281.10 million in cash and $5.56 million in debt, with a net cash position of $279.57 million or $6.30 per share.
| Cash & Cash Equivalents | 281.10M |
| Total Debt | 5.56M |
| Net Cash | 279.57M |
| Net Cash Per Share | $6.30 |
| Equity (Book Value) | 272.05M |
| Book Value Per Share | 7.28 |
| Working Capital | 266.66M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$81.63 million and capital expenditures -$719,000, giving a free cash flow of -$82.35 million.
| Operating Cash Flow | -81.63M |
| Capital Expenditures | -719,000 |
| Depreciation & Amortization | 213,000 |
| Net Borrowing | -6.00M |
| Free Cash Flow | -82.35M |
| FCF Per Share | -$1.86 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | -1,031.46% |
| Pretax Margin | -896.11% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
BioAge Labs does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -234.99% |
| Shareholder Yield | -234.99% |
| Earnings Yield | -11.25% |
| FCF Yield | -11.49% |
Analyst Forecast
The average price target for BioAge Labs is $51.50, which is 218.89% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $51.50 |
| Price Target Difference | 218.89% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 6 |
| Revenue Growth Forecast (5Y) | -31.25% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
BioAge Labs has an Altman Z-Score of 3.75 and a Piotroski F-Score of 1.
| Altman Z-Score | 3.75 |
| Piotroski F-Score | 1 |
